Cargando…

Biological and Immune Responses to Current Anti-SARS-CoV-2 mRNA Vaccines beyond Anti-Spike Antibody Production

Several vaccine strategies are now available to fight the current SARS-CoV-2 pandemic. Those based on the administration of lipid-complexed messenger(m)RNA molecules represent the last frontiers in terms of technology innovation. mRNA molecules coding for the SARS-CoV-2 Spike protein are intramuscul...

Descripción completa

Detalles Bibliográficos
Autor principal:	Federico, Maurizio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124111/ https://www.ncbi.nlm.nih.gov/pubmed/35607407 http://dx.doi.org/10.1155/2022/4028577

Ejemplares similares

Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
por: Greenberger, Lee M., et al.
Publicado: (2022)

The conundrum of current anti-SARS-CoV-2 vaccines
por: Federico, Maurizio
Publicado: (2021)

How Do Anti-SARS-CoV-2 mRNA Vaccines Protect from Severe Disease?
por: Federico, Maurizio
Publicado: (2022)

Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Impact of anti-PEG antibodies induced by SARS-CoV-2 mRNA vaccines
por: Ju, Yi, et al.
Publicado: (2022)

Correspondence on Body Weight, Anti-SARS-CoV-2 Antibody and mRNA Vaccination
por: Sookaromdee, Pathum, et al.
Publicado: (2023)

Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
por: Stellini, Roberto, et al.
Publicado: (2022)

Anti-Spike antibodies 3 months after SARS-CoV-2 mRNA vaccine booster dose in patients on hemodialysis: the prospective SENCOVAC study
por: Quiroga, Borja, et al.
Publicado: (2022)

Efficacy of anti-SARS-CoV-2 mRNA vaccine in systemic autoimmune disorders: induction of high avidity and neutralising anti-RBD antibodies
por: Tani, Chiara, et al.
Publicado: (2021)

Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination
por: Cho, Alice, et al.
Publicado: (2021)

SARS-CoV-2 mRNA vaccination is not associated with the induction of anti-HLA or non-HLA antibodies
por: Wijtvliet, Veerle P.W.M., et al.
Publicado: (2022)

Loss of anti‐spike antibodies following mRNA vaccination for COVID‐19 among patients with multiple myeloma
por: Stampfer, Samuel D., et al.
Publicado: (2023)

Anti-SARS-CoV-2 Spike Antibody Titers and Neutralizing Antibodies in Vaccinated Rheumatoid Arthritis Patients
por: Furukawa, Hiroshi, et al.
Publicado: (2022)

Influence of immunosuppressive therapy on longitudinal changes in anti-SARS-CoV-2 spike protein antibodies after two doses of mRNA vaccines in patients with rheumatic diseases
por: Kawazoe, Mai, et al.
Publicado: (2023)

Anti-SARS-CoV-2 mRNA vaccine in patients with rheumatoid arthritis
por: Rubbert-Roth, Andrea, et al.
Publicado: (2021)

Kinetics of dried blood spot-measured anti-SARS-CoV2 Spike IgG in mRNA-vaccinated healthcare workers
por: Puccini, Lucrezia, et al.
Publicado: (2023)

Anti-Spike Antibodies Present in the Milk of SARS-CoV-2 Vaccinated Mothers Are Complement-Activating
por: Agostinis, Chiara, et al.
Publicado: (2023)

SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
por: Bettini, Emily, et al.
Publicado: (2021)

Janus Emulsion Biosensors for Anti-SARS-CoV-2 Spike Antibody
por: Li, Jie, et al.
Publicado: (2021)

Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals
por: Brochot, Etienne, et al.
Publicado: (2020)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

SARS CoV2 mRNA vaccines: Prolonged dosing intervals and anti-SARS-CoV-2 immunity status
por: Ghazvini, Kiarash, et al.
Publicado: (2022)

Transient optic neuritis and perineuritis associated with anti-MOG antibody after SARS-CoV-2 mRNA vaccination
por: Singu, Takaomi, et al.
Publicado: (2022)

Seroconversion panels demonstrate anti-SARS-CoV-2 antibody development after administration of the mRNA-1273 vaccine
por: Belda, Francisco, et al.
Publicado: (2022)

Prior cycles of anti-CD20 antibodies affect antibody responses after repeated SARS-CoV-2 mRNA vaccination
por: Asashima, Hiromitsu, et al.
Publicado: (2023)

Broad anti-SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination
por: Kaku, Chengzi I., et al.
Publicado: (2022)

Anti-signal Recognition Particle Antibody-positive Immune-mediated Myopathy after mRNA-1273 SARS-CoV-2 Vaccination
por: Tanemoto, Masanobu, et al.
Publicado: (2022)

Successful Anti-SARS-CoV-2 Spike Protein Antibody Response to Vaccination in MAGT1 Deficiency
por: Jalil, Maaz, et al.
Publicado: (2021)

Persistence of Anti-SARS-CoV-2 Spike IgG Antibodies Following COVID-19 Vaccines
por: Alharbi, Naif Khalaf, et al.
Publicado: (2022)

SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
por: Jaycox, Jillian R., et al.
Publicado: (2023)

Humoral response after SARS-CoV-2 mRNA vaccines in dialysis patients: Integrating anti-SARS-CoV-2 Spike-Protein-RBD antibody monitoring to manage dialysis centers in pandemic times
por: Bachelet, Thomas, et al.
Publicado: (2021)

Impaired Humoral Immunity Identified in Inactivated SARS-CoV-2 Vaccine Recipients without Anti-Spike RBD Antibodies
por: Sun, Ting, et al.
Publicado: (2023)

Circulating anti-SARS-CoV-2 nucleocapsid (N)-protein antibodies and anti-SARS-CoV-2 spike (S)-protein antibodies in an African setting: herd immunity, not there yet!
por: Mveang Nzoghe, Amandine, et al.
Publicado: (2021)

The Screening of Broadly Neutralizing Antibodies Targeting the SARS-CoV-2 Spike Protein by mRNA Immunization in Mice
por: An, Zhiyin, et al.
Publicado: (2023)

No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1
por: Prasad, Mukul, et al.
Publicado: (2021)

Anti-SARS-CoV-2 spike IgG antibodies prevalence: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2023)

Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
por: Farkash, Inbal, et al.
Publicado: (2021)

SARS-CoV-2 anti–spike antibodies after vaccination in pediatric heart transplantation: A first report
por: Spinner, Joseph A., et al.
Publicado: (2022)

Potential for false decline of anti-SARS-CoV-2 spike antibody titers after COVID-19 vaccination
por: Waldman, Meryl, et al.
Publicado: (2022)

Affinity of anti-spike antibodies to three major SARS-CoV-2 variants in recipients of three major vaccines
por: Macdonald, Patrick J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qge8ma99531f12ffg1qv2me4jb